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Abstract
Introduction Amplification of the HER-2 receptor tyrosine
kinase has been implicated in the pathogenesis and aggressive
behavior of approximately 25% of invasive human breast
cancers. Clinical and experimental evidence suggest that
aberrant HER-2 signaling contributes to tumor initiation and
disease progression. Transforming growth factor beta (TGF-β)
is the dominant factor opposing growth stimulatory factors and
early oncogene activation in many tissues, including the
mammary gland. Thus, to better understand the mechanisms by
which HER-2 overexpression promotes the early stages of
breast cancer, we directly assayed the cellular and molecular
effects of TGF-β1 on breast cancer cells in the presence or
absence of overexpressed HER-2.
Methods Cell proliferation assays were used to determine the
effect of TGF-β on the growth of breast cancer cells with normal
or high level expression of HER-2. Affymetrix microarrays
combined with Northern and western blot analysis were used to
monitor the transcriptional responses to exogenous TGF-β1 in
luminal and mesenchymal-like breast cancer cells. The activity of
the core TGF-β signaling pathway was assessed using TGF-β1
binding assays, phospho-specific Smad antibodies,
immunofluorescent staining of Smad and Smad DNA binding
assays.
Results We demonstrate that cells engineered to over-express
HER-2 are resistant to the anti-proliferative effect of TGF-β1.
HER-2 overexpression profoundly diminishes the transcriptional
responses induced by TGF-β in the luminal MCF-7 breast
cancer cell line and prevents target gene induction by a novel
mechanism that does not involve the abrogation of Smad
nuclear accumulation, DNA binding or changes in c-myc
repression. Conversely, HER-2 overexpression in the context of
the mesenchymal MDA-MB-231 breast cell line potentiated the
TGF-β induced pro-invasive and pro-metastatic gene signature.
Conclusion HER-2 overexpression promotes the growth and
malignancy of mammary epithelial cells, in part, by conferring
resistance to the growth inhibitory effects of TGF-β. In contrast,
HER-2 and TGF-β signaling pathways can cooperate to
promote especially aggressive disease behavior in the context of
a highly invasive breast tumor model.
Introduction
HER-2 is a member of the type I receptor tyrosine kinase family
[1,2], which consists of four closely related family members,
HER-2 (neu/ErbB2), epidermal growth factor receptor (EGFR;
ErbB1), HER-3 (ErbB3) and HER-4 (ErbB4). Unlike the other
ErbB family members, HER-2 does not directly bind any ligand
with high affinity. Instead, the major role of HER-2 is to serve
as a co-receptor in the dimerization and activation of other
ErbB receptors [3,4]. Amplification of the HER-2 gene is
detected in approximately 25% of human breast cancers and
this genomic alteration is predictive of poor clinical outcome
[5-7]. HER-2 amplification results in a 50 to 100-fold increase
in the number of surface HER-2 receptors on cancer cells
compared to the normal mammary epithelium [8-10]. AberrantR1058
BSA = bovine serum albumin; DCIS = ductal carcinoma in situ; ECM = extracellular matrix; EGFR = epidermal growth factor receptor; EMT = epi-
thelial to mesenchymal transition; ER = estrogen receptor; FITC = fluorescein isothiocyanate; MAPK = mitogen-activated protein kinase; PBS = phos-
phate-buffered saline; SBE = Smad-binding element; TGF-β = transforming growth factor beta.
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R1059signaling through these receptors is believed to play a direct
role in malignant transformation and/or progression. Evidence
obtained in model systems supports the premise that progres-
sion of HER-2 amplified breast cancers is driven by HER-2
gene activity. When the level of engineered HER-2 expression
in tumor cell lines mimics the disease state, important pheno-
typic changes are observed, including increased growth in
vitro, decreased anti-estrogen response, increased produc-
tion of angiogenic factors, as well as increased tumorigenicity
and metastatic potential in vivo[11-15]. These changes paral-
lel the observed aggressive clinical behavior of human tumors
that contain an amplified HER-2 gene [5-7].
HER-2 gene amplification and oncogenic mutations constitu-
tively activate the HER-2 homodimeric tyrosine kinase [16-18].
Elevated HER-2 activity can reduce the general growth factor
dependence of HER-2 amplified cells though prolonged stim-
ulation of the Ras/Raf/Mitogen-activated protein kinase
(MAPK) pathway [16,17]. It is also increasingly clear that the
high cell-surface HER-2 density that accompanies gene ampli-
fication alters the normal equilibrium of ErbB dimers in favor of
HER-2 containing heterodimers, thus altering ligand depend-
ant signaling mechanisms [19]. The oncogenic potency of het-
erodimers, EGFR/HER-2 for example, is significantly
enhanced compared to EGFR homodimers by several proc-
esses that prolong receptor signaling activity [20-22]. The effi-
cient recruitment of the p85 subunit of phosphoinositide 3-
kinase by ligand-dependent stimulation of HER-2/HER-3 het-
erodimers is another important consequence of the shift
towards HER-2 containing heterodimers [23]. It is therefore
likely that HER-2 induced hypersensitivity to EGF family
growth factors may contribute significantly to tumor progres-
sion.
HER-2 amplification is a relatively early event in the clinical
pathogenesis of human breast cancer based on its frequent
occurrence in the pre-invasive lesion, ductal carcinoma in situ
(DCIS) [24-26]. The frequency of HER-2 amplification
detected in high grade (comedo) DCIS has been reported to
be as high as 77% [27]. This evidence suggests that aberrant
HER-2 activity plays an important role in tumor initiation as well
as in the emergence of aggressive cellular behavior associ-
ated with progressive disease. Experimental support for the
role of HER-2 in breast cancer initiation comes from trans-
genic experiments in which wild-type or activated HER-2
expressed in mouse mammary epithelium leads to a high fre-
quency of mammary carcinomas [28-30]. The histopathology
of these cancers closely resembles the human malignancy,
including the appearance of a DCIS-like lesion followed by
invasive disease. It has also been shown that activated HER-2
is uniquely capable of promoting a DCIS-like phenotype in in
vitro models of mammary acini [31].
In an effort to gain a better understanding of the mechanisms
by which elevated HER-2 signaling contributes to tumor initia-
tion, we investigated whether or not HER-2 antagonizes
growth inhibitory signals normally present in the breast epithe-
lium. The transforming growth factor beta (TGF-β) signaling
pathway is the dominant system opposing the stimulatory
effect of growth factors and early oncogene activation in many
tissues including the mammary gland [32]. TGF-β exposure
markedly suppresses mouse mammary tumor development
[32] and reversibly inhibits normal mammary gland growth
[33]. It is also well established that TGF-β potently inhibits the
growth of normal epithelial cells as well as some breast cancer
cell lines in culture [34,35]. Resistance to the anti-proliferative
effects of TGF-β appears at an early stage of tumor progres-
sion in a number of human malignancies. This occurs in some
cancers through mutational inactivation of the TGF-β receptor
genes (TβRII) or their signaling effectors SMAD2 or SMAD4
[36-38]. However, the growth inhibitory functions of TGF-β
signaling are more commonly subverted by epigenetic
changes that reduce receptor expression, prevent the nuclear
localization of Smad2 and Smad3 proteins, or functionally
inactivate them within a given gene regulatory complex [39].
The current study examines the interaction of the HER-2 and
TGF-β signaling pathways in the context of human breast can-
cer. The primary goal was to examine the potential role for
HER-2 overexpression in altering the growth inhibitory activity
of TGF-β signaling. The effects of HER-2 overexpression on
the TGF-β responses of two estrogen receptor (ER)-positive,
luminal breast tumor cell lines, MCF-7 and ZR-75-1, that are
experimentally non-invasive were examined. We found that
engineered HER-2 overexpression can abrogate TGF-β1
mediated gene responses in both MCF-7 and ZR-75-1 cells
and can render the highly sensitive cell line (MCF-7) resistant
to the growth inhibitory effects of TGF-β. The functions of
TGF-β, however, are not limited to growth inhibition and tumor
suppression. TGF-β can also promote invasive cell behavior
and metastasis [39] often associated with an epithelial to mes-
enchymal transition (EMT) [40]. To characterize the interaction
of the HER-2 and TGF-β pathways in this context, the effects
of HER-2 overexpression on the TGF-β response in the mes-
enchymal-like breast cancer cell line MDA-MB-231 were
examined. In this cellular background, the HER-2 and TGF-β
pathways appear to cooperate to promote an especially
aggressive phenotype.
Materials and methods
Cell lines, antibodies and cytokines
The HER-2 engineered cell lines (MCF-7 H2, ZR-75-1 H2 and
MDA-MB-231 H2) were generated by infection with a retrovi-
ral vector containing the human, full-length HER2 DNA as
described previously [13]. Control cell lines (CN) were gener-
ated for each cell line by simultaneous infection with the retro-
viral (pLSXN) vector. Cells were cultured in RPMI 1640
supplemented with 10% v/v fetal bovine serum, 100 U ml-1
penicillin (P) and 100 U ml-1 streptomycin at 37°C in a humid-
ified, 5% CO2 atmosphere. Rabbit polyclonal antibodies
Available online http://breast-cancer-research.com/content/7/6/R1058
R1060against p15INK4B and cdk4 (C-22) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). The mouse mon-
oclonal c-neu (Ab-3) antibody was purchased from Oncogene
Research Products (San Diego, CA, USA) and those against
Smad2 and Smad4 were obtained from Transduction Labora-
tories (BD, Lexington, KY, USA). Rabbit antibodies against
phospho-Smad2, and Smad3 were from Upstate (Lake Placid,
NY, USA) and Zymed (San Francisco, CA, USA), respectively.
Recombinant human TGF-β1, TGF-β2 and TGF-β3 (R&D Sys-
tems, Minneapolis, MN, USA) were diluted in acidified PBS
containing 0.1% w/v BSA (diluent control).
Cell proliferation assays
MCF-7 and ZR-75-1 cells were seeded at 8000 cells/well in
12 well plates and allowed to attach for 12 to 18 h after which
treatments were begun (equals day 0). Cells were treated with
recombinant TGF-β1 (0.2 to 0.8 ng/ml) and on the indicated
days, triplicate wells were harvested by trypsinization and
counted using a Coulter counter (Beckman Coulter, Fullerton,
CA, USA). MDA MB-231 CN and H2 cells were seeded at
500 cells/well in 96 well plates. After 24 h, increasing concen-
trations of TGF-β1, TGF-β2, and TGF-β3 (0.01 to 100 ng/ml)
were added and the cells were cultured for 6 days. The cells
were pulsed with 1 uCi [3H] thymidine/well (Perkin Elmer/
NEN, Boston, MA, USA) for the final 24 h. Triplicate wells for
each data point were harvested by trypsinization and thymi-
dine incorporation was measured using a 96-well TOMTEC
harvester (TOMTEC, Hamden, CT, USA).
RNA preparation and Northern blotting
Total RNA was purified using guanidinium/cesium chloride
ultracentrifugation, Trizol reagent (Gibco/Invitrogen, Carlsbad,
CA, USA) or RNeasy Midi kits (Qiagen, Valencia, CA, USA).
Total RNA (8 or 10 µg) was electrophoresed in 1% glyoxyl
gels and transferred to positively charged nylon membranes
(Ambion, Austin, TX, USA) using the Turbo Blotter apparatus
(Schleicher and Schuell, Keene, NH, USA) and the Northern
Max-Gly (Ambion) buffers. The cDNA probes were labeled by
random priming using 32 P-dATP (cDNA sequences available
upon request). Signals were quantified using a Phosphorim-
ager and ImageQuant software (Molecular Devices, Sunny-
vale, CA, USA).
Microarray analysis
Total RNA was isolated using the RNeasy Mini Kit (Qiagen).
The cells were disrupted in approximately 500 ul GITC (guani-
dine thiocyanate)-containing buffer per 106 cells. The samples
were homogenized by centrifugation (2 minutes at 14 K rpm)
through a QIAshredder spin column (Qiagen). The RNA qual-
ity was characterized with a RNA 6000 Nano Labchip (Agilent
Technologies, Palo Alto, CA, USA). The 28S/18S ribosomal
RNA ratios exceeded 1.7 and RNA yields averaged 40 pg per
cell. Total RNA was prepared for hybridization following the
manufacturer's protocols (Affymetrix, Santa Clara, CA, USA).
Fragmented cRNA was hybridized to HGU133A arrays and
scanned using a Agilent DNA Microarray Scanner. Expression
data were analyzed using Rosetta Resolver 3.0 (Rosetta Infor-
matics, Seattle, WA, USA).
Cell lysates, western blotting, and Smad2 
immunocytochemistry
Semi-confluent cells were harvested with trypsin and lysed in
modified RIPA buffer (PBS containing 1.0% v/v Triton X-100,
0.1% v/v SDS, 100 µM Phenylmethylsulfonyl fluoride (PMSF),
10 µg/ml leupeptin and 20 µg/ml aprotinin) at a concentration
of 2 to 4 × 106 cells/ml. Lysates were cleared of insoluble cel-
lular debris by centrifugation, subjected to SDS-PAGE and
transferred to PVDF membranes. All buffers, gels and mem-
branes were purchased from Invitrogen. After transfer and
blocking in TBS-T (saline buffered with 25 mM Tris-HCl (pH
7.4) containing 0.1% v/v Tween-20) containing 10% w/v non-
fat dry milk, membranes were incubated with primary antibod-
ies (diluted in TBS-T + 1% w/v milk) overnight at 4°C. After
washing, blots were incubated with anti-mouse or anti-rabbit-
HRP (Santa Cruz Biotechnology). Antibody complexes were
detected with the ECL chemiluminescent system (Amersham/
Pharmacia, Piscataway, NJ, USA). For Smad2 immunohisto-
chemistry, cells were grown for 24 to 48 h on 4 well-cham-
bered slides and treated for 1 h with media containing 2 ng/ml
TGF-β1 or diluent control. Cells were then fixed in 4% parafor-
maldehyde with 0.1% Triton X-100 for 15 minutes, washed in
PBS and incubated with the anti-Smad2 antibody diluted
1:500 in blocking buffer (1 × PBS with 2% w/v BSA and 10%
v/v normal goat serum) overnight at 4°C. After washing, cells
were reacted with a 1:800 dilution of Alexa-488 labeled goat
anti-mouse IgG (Molecular Probes, Eugene, OR, USA) for flu-
orescent visualization. Alternatively for the enzymatic staining,
after primary antibody incubation, the cells were incubated
with a 1:75 dilution of unlabeled goat anti-mouse IgG followed
by a 1:75 dilution of mouse peroxidase anti-peroxidase com-
plex (PAP; Zymed, San Francisco, CA, USA) and antibody
complexes were visualized with DAB (3,3' diaminobenzidine)
substrate (Sigma, St Louis, MI, USA).
Ligand binding and DNA binding assays
The Fluorokine kit (R&D Systems) was used to measure bind-
ing of fluorescein isothiocyanate (FITC)-labeled recombinant
TGF-β1 to the surface of live breast cancer cells. Cells were
harvested, filtered to produce single cell suspensions,
counted and reacted with labeled TGF-β1 or control protein
according to manufacturer's specifications. The Smad DNA
binding assay was performed using biotinylated, double-
stranded oligonucleotides whose sequence contained the
three Smad binding element (SBE) sites and the E-box from
the PAI-1 promoter previously described as PE2 [41]. The
mutated oligo (PE1m12,3) was also synthesized as previously
described [41]. Nuclei were isolated from cells treated for 1 h
with either diluent control or 2 ng/ml TGF-β1 using the Nuclei
EZ lysis buffer as recommended by the manufacturer (Sigma).
Nuclear extracts were prepared by resuspending pelleted
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by vortexing and sonication and finally centrifugation to clear
insoluble material. The nuclear extracts were reacted with the
wild-type or mutated oligonucleotide for 3 h. DNA-protein
complexes were collected using streptavidin-labeled sepha-
rose (Amersham Pharmacia) and after extensive washing,
complexes were electrophoresed on SDS-PAGE gels. The
presence of Smad2, Smad3 and Smad4 proteins in the com-
plexes was detected by western blotting.
Results
Expression profiling reveals that HER-2 overexpression 
alters components of the TGF-β signaling pathway
We initially performed a genome-wide assessment of the dif-
ferential gene activity associated with HER-2 overexpression
in the MCF-7 breast cancer cell line using cDNA and filter
arrays. These transcript profiling data revealed a pattern of
changes consistent with a loss of TGF-β signal transduction in
MCF-7 cells with elevated levels of HER-2 (Additional file 1).
Several TGF-β superfamily ligands and receptors had signifi-
cantly altered expression in association with HER-2 overex-
pression. We detected significant expression changes in five
TGF-β ligand genes (TGF-β2, TGF-β3, BMP-3, BMP-5 and
BMP-7) and two receptors, the TGF-β type II receptor (TBRII)
and endoglin. This observation prompted a query of the array
data for genes reported to be activated in response to TGF-β.
Eight such genes were identified, all of which had significantly
lower transcript levels in the MCF-7 H2 cells. A theme of the
TGF-β pathway and the presumed function of these genes is
the regulation of cell growth and extracellular matrix (ECM)
deposition. The products of these eight TGF-β inducible
genes include: alpha-1 collagens (type III, V, XVIII); CTGF and
CYR61, members of the CCN family of secreted proteins that
function as mitoattractants and as regulators of cell migration/
adhesion [42]; β-Ig-H3/TGFBI, a secreted protein that has a
role in cell-collagen adhesion interactions [43]; TIMP2, an
inhibitor of matrix metalloproteinases (such as collagenases)
[44,45]; and Endothelin 1 (ET1) a secreted protein with vaso-
constrictive properties [46]. The consistent suppression of
TGF-β activated genes in association with HER-2 overexpres-
sion suggests that TGF-β signaling is inhibited in MCF-7 H2
cells. Together these expression changes provided the ration-
ale to further examine the biological consequences and the
potential mechanistic interaction of the HER-2 and TGF-β sig-
naling pathways in MCF-7 cells and in additional cell line mod-
els.
Biological effects of TGF-β1 on breast cancer cells with 
elevated HER-2
Experiments were performed to determine if engineered HER-
2 overexpression can alter cellular response to exogenous
TGF-β1 in human breast cancer cells. The effect of TGF-β on
the growth of previously generated [13] HER-2 overexpress-
ing (H2) and vector control (CN) sub-lines of MCF-7, ZR-75-
1 and MDA-MB-231 cells was investigated. A significant dif-
ference in TGF-β1 sensitivity was observed in the MCF-7 CN
compared to MCF-7 H2 cells (Fig. 1a–c). MCF CN cells grew
logarithmically (with a 49-fold increase in cell number) over 7
days of treatment whereas the same cells exposed to TGF-β1
showed only a 2 to 7-fold increase in cell number (Fig. 1a). In
contrast, the inhibitory effect of TGF-β1 on MCF-7 H2 cells
was minimal, with the number of cells in all treatment groups
increasing by 60-fold over 7 days (Fig. 1b). In terms of percent
inhibition, the MCF-7 CN cells were 80% growth inhibited at
the lowest dose of TGF-β1 whereas the MCF-7 H2 cells were
not significantly inhibited (Fig. 1c). The ZR-75-1 CN cells were
essentially resistant to growth inhibition by TGF-β1 with or
without HER-2 overexpression (Fig. 1d). It has been reported
that parental ZR-75-1 cells over-express mdm2, which pro-
vides an independent mechanism for acquiring TGF-β1 resist-
ance [47]. The MDA-MB-231 cell line is highly motile and
invasive, carries an activated Ki-ras allele and appears pheno-
typically to have undergone EMT [48-50]. MDA-MB-231 CN
cells were resistant to growth inhibition by TGF-β1-3 in vitro
(Fig. 1e). The MDA-MB-231 H2 cells were not only resistant
to growth inhibition by TGF-β1, but were growth stimulated by
doses greater than 1 ng/ml of all three TGF-β ligands (Fig. 1e).
The MDA-MB-231 cells were also stimulated morphologically
to aggregate, forming obvious piles or colonies in culture (Fig.
1f). This effect was not observed in the MDA-MB-231 CN
cells, even at relatively high concentrations of TGF-β1 (up to
20 ng/ml). Thus the 'piling' phenotype appears to require both
TGF-β1 treatment and HER-2 overexpression.
Markers of TGF-β pathway activity are reduced in both 
MCF-7 and ZR-75-1 cells in association with HER-2 
overexpression
In an attempt to interpret the different biological responses of
breast cancer cells to TGF-β treatment, the mRNA expression
levels of the TBRII and five previously recognized TGF-β
response genes identified in our initial expression profiling
experiments (Additional file 1), along with the well-character-
ized TGF-β inducible gene PAI-1 [51-53], were evaluated by
Northern blotting (Fig. 2). The two ER-positive, luminal cell
lines (MCF-7 and ZR-75-1) exhibited very similar TGF-β
marker gene expression patterns with low-level TBRII and
TGFB2 expression and low to moderate expression of TGF-β
downstream target genes PAI-1, CYR61, CTGF, TIMP2, and
IGFBP5. Conversely, the MDA-MB-231 cells displayed a very
different TGF-β marker profile with higher levels (>10-fold) of
TBRII and TGFB2, as well as significantly higher expression of
4/5 of the downstream target genes, PAI-1, CYR61, CTGF,
TIMP2. These results underscore the differences between
cells that have undergone EMT (MDA-MB-231) [49,50] and
those that have not (MCF-7 and ZR-75-1) and are consistent
with reports demonstrating that TGF-β is a critical mediator of
EMT [54-56].
We next assessed the effects of HER-2 overexpression on the
TGF-β pathway genes in the matched H2 cell lines. A marked
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R1062Figure 1
HER-2 overexpression modulates transforming growth factor (TGF)-β responses in a cell context dependent manneri f t  ( )-  r  i  a cel  context dependent anner. (a-c) HER-2 overexpression in 
MCF-7 breast cancer cells blocks TGF-β mediated growth arrest. CN and H2 cells were treated with diluent control (diamonds) or TGF-β1 (0.2 ng/
ml (black circles); 0.4 ng/ml (white circles); or 0.8 ng/ml (triangles)) and counted on the indicated days after treatment. Each point is the average of 
triplicate wells (± standard deviation for error bars). (a) The growth of MCF-7 CN cells is severely inhibited by TGF-β1. (b) MCF-7 H2 cells are 
resistant to growth inhibition by TGF-β1. (c) MCF-7 CN (diamonds) versus MCF-7 H2 (white circles) cells treated with 0.2 ng/ml TGF-β1. (d) ZR-
75-1 cells are resistant to growth inhibition by TGF-β1 without HER-2 overexpression (ZR-75-1/CN (diamonds) versus ZR-75-1/H2 (white circles)) 
treated with 0.2 ng/ml TGF-β1. (e) TGF-β1 stimulates the growth of MDA-MB-231 H2 cells. MDA MB-231 CN (diamonds) and H2 cells (white cirl-
cles) were grown for 6 days in the presence of TGF-β1, β2 or β3 (0.01 to 100 ng/ml) or a diluent control. Cells were pulsed with [3H] thymidine for 
the final 24 h of assay and thymidine incorporation was measured. The average counts of triplicate wells for each data point are represented as % of 
diluent control. (f) TGF-β induces a 'piling' phenotype in MDA-MB-231 that is dependent on HER-2 overexpression. MDA-MB-231 CN and H2 cells 
were grown for 5 days in the presence of 10 ng/ml TGF-β1 or diluent control. Cells were stained with crystal violet dye and photographed with a 
20× (top four panels) or a 60× (bottom two panels) objective.
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(TBRII, TGFB2, PAI-1, CYR61, CTGF, and TIMP2) was con-
sistently observed in both MCF-7 and ZR-75-1 cells that over-
expressed HER-2 despite their diverse genetic backgrounds
and biological properties (Fig. 2). In contrast, expression levels
of TGF-β pathway genes were not reduced in association with
HER-2 overexpression in the MDA-MB-231 cells. These data
suggest that the TGF-β transcriptional program may be gener-
ally abrogated in response to HER-2 overexpression in the
MCF-7 and ZR-75-1 cells. The high expression of TGFB2,
TBRII and downstream TGF-β target genes observed in the
MDA-MB-231 cells suggests that the TGF-β pathway is con-
stitutively activated and, in this context, HER-2 overexpression
does not appear to inhibit TGF-β gene responses.
HER-2 overexpression diminishes the TGF-β1 induced 
transcriptional program
To directly assess whether HER-2 overexpression inhibits
TGF-β1 mediated gene induction in the MCF-7 and ZR-75-1
cells, we assayed the expression of three TGF-β target genes,
CTGF, PAI-1 and p15INK4B in response to exogenous, recom-
binant TGF-β1. These genes contain SBEs and have been
extensively utilized to evaluate Smad-dependant TGF-β signal-
ing activity [51,52,57,58]. The MCF-7 CN and ZR-75-1 CN
cell lines each showed increased levels of CTGF and PAI-1
mRNA in response to TGF-β1, with the induction of CTGF and
PAI-1 peaking at 8 and 24 h post TGF-β exposure, respec-
tively (Fig. 3a). Little or no induction of either gene was
observed in the same cell lines engineered to overexpress
HER-2 (Fig. 3a, asterisks). Moreover, induction of the cdk4
inhibitor p15INK4B, a central mediator of TGF-β induced cell
cycle arrest [58], was also abrogated by HER-2 overexpres-
sion in both MCF-7 and ZR-75-1 cells (Fig. 3b, asterisks).
To investigate whether or not HER-2 overexpression affects
the global TGF-β gene expression program, microarray exper-
iments were performed. We profiled the expression changes
in MCF-7 CN and MCF-7 H2 cells induced by exposure to
exogenous, recombinant TGF-β1 for 6 or 24 h (Additional files
2, 3, 4, 5). A 6 h TGF-β exposure resulted in altered expression
(>1.5-fold change; p < 0.01) of approximately 0.3% of the
total elements represented on the arrays in both the MCF-7
CN and MCF-7 H2 cells (76 and 62 elements, respectively).
After 24 h of exposure, this number rose significantly to 352
elements (1.6% of total) in the MCF-7 CN cells but increased
only modestly to 81 elements (0.4% of total) in the MCF-7 H2
cells. The 24 h point was included because the PAI-1 and
p15INK4B expression data indicated that alterations in key
Smad-regulated gene expression can take 24 h to become
apparent (Fig. 3). Genes induced or repressed by TGF-β in
MCF-7 CN and MCF-7 H2 cells after 24 h were grouped into
broad categories (cell cycle, transcription factor, cytoskeleton)
by gene ontology (Table 1). The overwhelming majority of the
TGF-β response is eliminated in cells that overexpress HER-2
(MCF-7 H2) (Table 1; Fig. 4b). This set of genes includes
Figure 2
Expression of TGF-β pathway genes in control (CN) and HER-2 overex-pressing (H2) breast c ncer cells
pressing (H2) breast cancer cells. Northern analysis of HER-2 mRNA 
and transforming growth factor (TGF)-β markers in MCF-7, ZR-75-1 
and MDA-MB-231 cells with (H2) and without (CN) HER-2 overexpres-
sion. Message levels were assayed from 10 ug of total RNA. Asterisks 
indicate consistent and significant down-regulation (> 2-fold as meas-
ured by phosphorimager quantification). The image of the 28S and 18S 
ribosomal RNA bands from the ethidium bromide stained gel is shown 
as a loading control.
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such as SMAD3 (MADH3) and the TGF-β inducible early
growth response gene (TIEG) as well as genes activated later,
such as the cytoskeleton associated genes (Paxillin, (PXN)).
Specifically in terms of TGF-β activated genes, none of the
transcription factors, cell cycle or cytoskeleton regulating
genes induced by TGF-β in MCF-7 CN were significantly
induced in MCF-7 H2 cells (Table 1). The level of TIEG expres-
sion increased at the 6 h time point in MCF-7 CN cells. It is
particularly interesting, however, that this transcriptional acti-
vator is not significantly activated in the MCF-7 H2 cells as
TIEG has been shown to be a critical mediator of many TGF-β
effects and can, by itself, recapitulate the growth inhibitory
effects of TGF-β [59-61].
A residual TGF-β gene activation response is observed in the
MCF-7 H2 expression profile (Table 1). This includes genes
associated with the ECM or cellular adhesion such as collagen
V and the Ig superfamily member IGSF4, which were similarly
induced in the MCF-7 CN and MCF-7 H2 cells. Other genes
such as MSMB (encodes microseminoprotein beta) were
highly induced by TGF-β in MCF-7 CN cells but only moder-
ately induced in the MCF-7 H2 cells.
The most prominent feature in the TGF-β repressed gene set
in MCF-7 CN cells is the signature of cell cycle arrest (Table
1). This signature is composed of multiple cyclins (CCNA2,
CCNE2, CCNB1 and CCNB2) and S-phase and M-phase
specific proteins (CDC2, CDC20, NEK2, and CDC25C) as
well as proliferation markers such as Ki67 (MKI67), TOPO2A
and PCNA. It also includes several mitotic, chromosome seg-
regation and cytokinesis checkpoint and regulating genes
(BUB1, CENPA, CENPF and PRC1) as well as a large
number of genes regulating DNA synthesis, metabolism, and
repair (HELLS, LIG1, BARD1, BRIP1, RAD51C, and RCF2/
4/5). The majority of changes (31/37; 81%) in the cell cycle
arrest profile are absent in the MCF-7 H2 experiments. None
of the transcription factors repressed in MCF-7 CN cells,
including MXD3 (down-regulated 22-fold), were repressed in
the MCF-7 H2 cells. These data are entirely consistent with
the TGF-β mediated growth inhibition studies shown above
(Fig. 1a).
HER-2 overexpression abrogates the TGF-β mediated 
gene response by a novel mechanism
To evaluate the potential mechanisms by which HER-2 overex-
pression inhibits TGF-β1 mediated gene activation in luminal
breast cancer cells, the status of the core TBRI/TBRII/Smad
signal transduction pathway in MCF-7 CN and H2 cells was
investigated. Ligand binding was measured using FITC-
labeled TGF-β1 and flow cytometric analysis. Evidence of
TGF-β1 binding was obtained in both MCF-7 CN and H2 cells
as indicated by a 2.2 to 2.3-fold shift in median fluorescence
(FL1-H) upon addition of FITC-labeled TGF-β1 to live, single-
cell suspensions (Fig. 5a, green curves). The shift in fluores-
cence was completely blocked by excess unlabeled TGF-β1
or by pre-incubation of the FITC-TGF-β1 with anti-TGF-β1
antibodies (data not shown), indicating that ligand binding was
specific. In addition, no shift in fluorescence was observed
with a labeled irrelevant protein compared to untreated cells
(Fig. 5a). No significant difference in ligand binding was
detected in MCF-7 CN compared to MCF-7 H2 cells.
Phosphorylation and nuclear translocation of Smad2 were
evaluated next as measures of active receptor status in cells
treated with TGF-β1. Phospho-Smad2 was detected after 30
minutes of TGF-β treatment in the MCF-7 CN cells (Fig. 5b).
Phospho-Smad2 was also reproducibly detected in the MCF-
7 H2 cells, although it was somewhat reduced compared to
the CN cells. Endogenous Smad2 was found to translocate to
the nucleus equally well in MCF-7 CN and MCF-7 H2 cells
after treatment with TGF-β1 for 1 h (Fig. 5c) as measured by
immunocytochemistry.
We next investigated whether a defect in TGF-β induced
Smad DNA-binding activity could be detected in the MCF-7
H2 cells. Biotinylated oligonucleotides encoding the PE2 ele-
ment from the PAI-1 promoter [41] were used to examine the
extent of association between Smad proteins (Smad2, Smad3
Figure 3
HER-2 overexpression inhibits transforming growth factor (TGF)-β1 tar-get gene induction n the luminal MCF-7 and ZR-75-1 breast cancer c lls
get gene induction in the luminal MCF-7 and ZR-75-1 breast cancer 
cells. (a) Northern blot analysis of CTGF and PAI-1 expression. The 
membrane contained total RNA from the indicated CN and H2 cells 
treated with either diluent control (0 h) or 2 ng/ml TGF-β1 (8 or 24 h). 
(b) HER-2 overexpression prevents p15INK4B induction in MCF-7 and 
ZR-75-1 cells by TGF-β1. Western blot analysis of total cellular 
extracts prepared after treatment with diluent control (0 h) or 2 ng/ml 
TGF-β1 (8, 24 or 52 h). Bottom panels are the same membranes re-
probed with an antibody to cdk4.
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Dominant transforming growth factor-β gene signatures in the luminal MCF-7 CN and MCF-7 H2 cell lines
Sequence namea Sequence descriptionb Fold ∆ MCF-7 CNc Fold ∆ MCF-7 H2d Gene ontologye
TGF-β induced genes
BCL3 B-cell chronic lymphocytic Leukemia (CLL)/lymphoma 
3
1.70 Cell cycle
BACE Beta-site amyloid precursor protein (APP)-cleaving 
enzyme
2.86 ECM/adhesion
CD59 CD59 antigen p18-20 1.74 (3) ECM/adhesion
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) 1.94 ECM/adhesion
COL18A1 Collagen, type XVIII, alpha 1 1.91 ECM/adhesion
COL5A1 Collagen, type V, alpha 1 5.01 (2) 4.22 (2) ECM/adhesion
IGSF4 Immunoglobulin superfamily, member 4 1.94 1.81 ECM/adhesion
SCARB1 Scavenger receptor class B, member 1 1.77 ECM/adhesion
SPOCK Sparc/osteonectin (testican) 8.23 ECM/adhesion
THBS1 Thrombospondin 1 2.31 (3) ECM/adhesion
BMP7 Bone morphogenetic protein 7 (osteogenic protein 1) 2.05 Secreted factor
IGFBP5 Insulin-like growth factor binding protein 5 4.56 Secreted factor
MSMB microseminoprotein, beta- 11.19 (2) 3.65 (2) Secreted factor
CBFA2T3 Core-binding factor, runt domain, alpha subunit 2 2.06 Transcription factor
DZIP3 Zinc finger DAZ interacting protein 3 1.93 Transcription factor
ELK3 Sapiens cDNA: FLJ22425 fis, clone HRC08686 1.90 Transcription factor
FOXO1A Forkhead box O1A (rhabdomyosarcoma) 3.45 (2) Transcription factor
MADH3 MAD, mothers against decapentaplegic homolog 3 4.77 Transcription factor
NRBP Nuclear receptor binding protein 2.12 Transcription factor
PLU-1 Putative DNA/chromatin binding motif 1.75 (2) Transcription factor
SOLH Small optic lobes homolog (Drosophila) 1.86 Transcription factor
TGIF Transforming growth factor beta (TGFB)-induced factor 
(TALE family homeobox)
1.70 Transcription factor
TIEG Transforming growth factor beta (TGFB) inducible early 
growth response
1.77 Transcription factor
TGF-β repressed 
genes
BIRC5 Baculoviral inhibitor of apoptosis (IAP) repeat-
containing 5 (survivin)
-3.04 Apoptosis
CCNA2 Cyclin A2 -2.18 Cell cycle
CCNB1 Cyclin B1 -1.99 Cell cycle
CCNB2 Cyclin B2 -1.94 Cell cycle
CCNE2 Cyclin E2 -2.03 Cell cycle
CDC2 Cell division cycle 2, G1 to S and G2 to M -2.62 (2) -1.77 (2) Cell cycle
CDC20 CDC20 cell division cycle 20 homolog (S. cerevisiae) -2.10 Cell cycle
CDC25C Cell division cycle 25C -2.02 Cell cycle
CDKN2C Cyclin-dependent kinase inhibitor 2C (p18, inhibits 
CDK4)
-2.59 Cell cycle
CDKN3 Cyclin-dependent kinase inhibitor 3 -2.66 Cell cycle
CKS1B CDC28 protein kinase regulatory subunit 1B -1.96 Cell cycle
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MKI67 Antigen identified by monoclonal antibody Ki-67 -2.26 (2) -2.84 Cell cycle
MPHOSPH9 M-phase phosphoprotein 9 -1.86 Cell cycle
NEK2 NIMA (never in mitosis gene a)-related kinase 2 -2.93 Cell cycle
ASPM asp (abnormal spindle)-like, microcephaly associated -2.48 Chromosome reg.
BUB1 BUB1 budding uninhibited by benzimidazoles 1 
homolog
-2.08 -1.72 Chromosome reg.
BUB1B BUB1 budding uninhibited by benzimidazoles 1 
homolog β
-1.78 Chromosome reg.
CENPA Centromere protein A, 17 kDa -2.53 Chromosome reg.
CENPE Centromere protein E, 312kDa -9.38 -4.87 Chromosome reg.
CENPF Centromere protein F, 350/400 kDa (mitosin) -2.42 Chromosome reg.
CNAP1 Chromosome condensation-related Structural 
maintenance of chromosomes (SMC)-associated 
protein 1
-1.99 Chromosome reg.
ESPL1 Extra spindle poles like 1 (S. cerevisiae) -2.62 Chromosome reg.
HCAP-G Chromosome condensation protein G -2.29 (2) -1.90 Chromosome reg.
HEC Highly expressed in cancer, rich in leucine heptad 
repeats
-4.35 -2.32 Chromosome reg.
PRC1 Protein regulator of cytokinesis 1 -2.23 Chromosome reg.
SMC2L1 SMC2 structural maintenance of chromosomes 2-like 1 -3.27 -1.70 Chromosome reg.
ZWINT ZW10 interactor -1.75 Chromosome reg.
BARD1 BRCA1 associated RING domain 1 -1.92 DNA metabolism
BRIP1 BRCA1 interacting protein C-terminal helicase 1 -1.71 DNA metabolism
CDT1 DNA replication factor -1.70 DNA metabolism
PIR51 RAD51-interacting protein -2.17 DNA metabolism
POLD1 Polymerase (DNA directed), delta 1, catalytic subunit -2.68 DNA metabolism
POLE2 Polymerase (DNA directed), epsilon 2 (p59 subunit) -1.78 DNA metabolism
PRIM1 Primase, polypeptide 1, 49 kDa -1.76 DNA metabolism
RAD51C RAD51 homolog C (S. cerevisiae) -1.72 DNA metabolism
RFC4 Replication factor C (activator 1) 4, 37 kDa -1.72 DNA metabolism
TOP2A Topoisomerase (DNA) II alpha 170 kDa -2.68 (2) DNA metabolism
ID1 Inhibitor of DNA binding 1, dominant negative HLH 
protein
-1.74 Transcription factor
MXD3 MAX dimerization protein 3 -22.10 Transcription factor
MYBL1 v-myb myeloblastosis viral oncogene homolog-like 1 -2.09 Transcription factor
MYBL2 v-myb myeloblastosis viral oncogene homolog-like 2 -2.07 Transcription factor
a,bThe primary sequence names and descriptions for the differentially regulated genes (defined as greater or equal to 1.7-fold changed with a p-
value of < 0.01) were extracted using Rosetta Resolver. Genes from the dominant ontology classes are shown and thus genes with unknown 
function or those not in well represented ontology classes are not listed. The complete set of differentially expressed genes can be found in 
Additional files 2, 3, 4, 5. cFold change in expression of the induced or repressed genes in the MCF-7 CN cell line after a 24 h exposure to 2 ng/
ml recombinant transforming growth factor (TGF)-β1 compared to the diluent treated controls. The number in parentheses after the fold change 
indicates the number of affected elements that were averaged to calculate the fold difference. dFold change in expression of the induced or 
repressed genes in the MCF-7 H2 cell line after a 24 h exposure to 2 ng/ml recombinant TGF-β1 compared to the diluent treated controls. The 
number in parentheses to the right of the fold change indicates the number of affected elements that were averaged to calculate the fold 
difference. eThe gene ontology annotation was curated from the Summary Function and GO fields downloaded from SOURCE [105].
Table 1 (Continued)
Dominant transforming growth factor-β gene signatures in the luminal MCF-7 CN and MCF-7 H2 cell lines
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stimulation (Fig. 5d). TGF-β1 treatment induced a specific
association between Smad2, Smad3 and Smad4 and the
wild-type PE2 oligonucleotides whereas no significant associ-
ation was observed using the control element where the criti-
cal first SBE site was mutated (i.e. PE2Sm1) [41]. The extent
of Smad DNA binding was indistinguishable in the MCF-7
parental, CN and H2 cells in this assay. In summary, these data
indicate that HER-2 overexpression can abrogate TGF-β1
mediated gene induction without preventing ligand binding,
Smad2 nuclear accumulation or Smad DNA binding.
TGF-β induction of p15INK4B does not depend on c-myc 
repression in MCF-7 cells
The repression of c-myc has been shown to be required for the
induction of p15INK4B by TGF-β and it has previously been
Figure 4
Context specific effects of HER-2 overexpression on the biological responses and transcription program induced by transforming growth factor (TGF)-β in breast cancer cells
(TGF)-β in breast cancer cells. (a) Phenotypes of the luminal MCF-7 and mesenchymal MDA-MB-231 cells with and without engineered HER-2 
overexpression. The epithelial growth pattern of MCF-7 cells is characteristically altered by HER-2 overexpression, which promotes an elongated 
morphology and increased proliferation rates in vitro as well as faster growing tumor xenografts in vivo [12,13]. The MDA-MB-231 cells are hetero-
geneous with the majority of cells, having a spindle shaped morphology. The effect of HER-2 overexpression on the morphological appearance was 
not dramatic except that significantly more (approximately three times) of the large, flattened round cells were observed. The MDA-MB-231 H2 cells 
have also been shown to be more metastatic in vivo than the MDA-MB-231 CN or parental lines (data not shown). (b) Summary of the TGF-β tran-
scriptional program obtained by Affymetrix microarray profiling of cells treated with recombinant TGF-β1. The number of elements significantly 
affected (p < 0.01 and fold change greater than ± 1.7 using Rosetta Resolver) are graphed. Light and dark red indicate genes upregulated after 6 h 
and 24 h, respectively, and light and dark green represent genes downregulated after 6 and 24 h, respectively. (c) Highlighted genes from the dom-
inant functional gene signatures as determined by the gene ontology information found in Source [105] and GeneCards [106]. Red and green indi-
cate TGF-β stimulated and repressed genes, respectively. ECM, extracellular matrix.
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HER-2 overexpression does not alter transforming growth factor (TGF)-β1 induced Smad2 activation or nuclear accumulation or the formation of Smad-Smad-binding elem nt (SBE) complexes
Smad-Smad-binding element (SBE) complexes. (a) TGF-β1 binds equally well to the surface of MCF-7 CN and MCF-7 H2 cells. The binding of flu-
orescein isothiocyanate (FITC)-labeled recombinant TGF-β1 was monitored by flow cytometry. The red curves show the FL1 values for the untreated 
control cells, the purple (filled) curves indicate the intensity of cells incubated with an irrelevant FITC-labeled protein and the green curves show the 
intensity of cells treated with FITC-labeled recombinant TGF-β1. The median shift in FL1 values (fold increase) between the irrelevant control protein 
and TGF-β1 is indicated. (b) TGF-β1 induced phosphorylation of Smad2 is detected in both MCF-7 CN and MCF-7 H2 cells. A phospho-specific 
Smad2 antibody was used on immunoblots of whole cell lysates from diluent or TGF-β1 treated cells. The blot was re-probed with an antibody 
against total Smad2, which cross-reacts weakly with Smad3. (c) Endogenous Smad2 is concentrated in the nucleus after exposure to TGF-β1 in 
MCF-7 or MDA-MB-231 cells with or without HER-2 overexpression. Vector control (CN) cells (left panels) or HER-2 overexpressing (H2) cells 
(right panels) were treated for 1 h with either diluent control or 2 ng/ml TGF-β1, fixed and stained with the anti-Smad2 antibody. The endogenous 
Smad2 protein was visualized with either a peroxidase/3,3'-Diaminobenzidine (DAB) reaction (top two rows) or an Alexa-488 conjugated secondary 
antibody (bottom row). (d) TGF-β1 stimulated Smad DNA binding is not affected by HER-2 overexpression in MCF-7 cells. Nuclear protein extracts 
from MCF-7 parental (PAR), MCF-7 CN and MCF-7 H2 cells treated with either diluent or TGF-β1 were reacted with biotin labeled oligonucleotides 
containing SBEs. Avidin-coupled sepharose beads were used to collect the DNA-protein complexes. The Smad composition of the complexes was 
analyzed by western blotting with anti-Smad antibodies as indicated. The last two lanes (CNmt) contained the same MCF-7 CN nuclear extract as in 
lanes 3–4, with a mutant oligonucleotide in which one of the SBE sites was mutated (i.e. PE2Sm1 [41]).
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β resistance mechanism in MCF-10A cells transformed by a
combination of ras and HER-2 [63,64]. We therefore exam-
ined whether or not c-myc expression was different in the
MCF-7 CN compared to the MCF-7 H2 cells in response to
TGF-β1 treatment. Surprisingly, c-myc mRNA was not
repressed by short (6 h) or longer-term (24 h) exposure to
TGF-β in the MCF-7 CN or H2 cells (Fig. 6). Instead, a small
but reproducible increase (1.3 to 1.4-fold) in c-myc message
levels was detected by Northern blot analysis. This same small
increase was also confirmed in the transcript ratios detected
by the Affymetrix chips. The only difference between the MCF-
7 CN and MCF-7 H2 cells with respect to the c-myc message
was an overall reduction in the H2 cells (MCF-7 H2 versus
CN, ZR-75-1 H2 versus CN and MDA-MB-231 H2 versus
CN; Fig. 6 and data not shown). The p15INK4B protein was
clearly induced by TGF-β treatment in these same MCF-7 CN
cells without repression of c-myc mRNA (Fig. 6). Thus, the
transcriptional repression of c-myc does not appear to be crit-
ical for the activation of the TGF-β cytostatic gene response or
the resulting cell cycle arrest in MCF-7 cells.
HER-2 overexpression potentiates the TGF-β induced 
invasion/angiogenic signature in MDA-MB-231 cells
As we have observed for MCF-7 cells, HER-2 overexpression
does not appear to inhibit activation of Smad2 in MDA-MB-
231 cells as Smad2 concentrates in the nucleus after TGF-β1
treatment in both MDA-MB-231 CN and MDA-MB-231 H2
cells (Fig. 5c). Thus HER-2 overexpression, oncogenic ras
[48], or the two combined do not prevent nuclear translocation
of Smad2 in response to TGF-β. Nevertheless, we have shown
that TGF-β treatment has markedly different biological effects
on the luminal MCF-7 cells compared to the mesenchymal-like
MDA-MB-231 cells (Fig. 1). In an effort to understand these
differential effects, additional microarray profiles were gener-
ated for both the MDA-MB-231 CN and H2 cells exposed to
exogenous, recombinant TGF-β1 for 6 or 24 h (Additional files
6, 7, 8, 9). A 6 h TGF-β exposure resulted in altered expression
(>1.5-fold; p < 0.01) of three times as many elements in the
MDA-MB-231 H2 cells (306 elements; 1.4% of the total) as in
the MDA-MB-231 CN cells (92 elements; 0.4%). The 24 h
exposure affected about twice as many elements as the 6 h
time point in both the MDA-MB-231 H2 cells (605 elements;
2.7% of total) and the MDA-MB-231 CN cells (206 elements;
0.9% of total). This overall pattern of gene induction in the
MDA-MB-231 cells was very different from that observed in
the MCF-7 experiments (Table 2, Figs 4b and 7). There was
little overlap (<10%) in the TGF-β signatures from the MCF-7
and MDA-MB-231 cells and HER-2 overexpression in the
MDA-MB-231 cell line greatly increased the magnitude and
the complexity of the TGF-β gene response rather than abro-
gating the response as seen in MCF-7 cells (Figs 4b and 7).
More genes were induced rather than repressed by TGF-β
treatment of MDA-MB-231 cells in contrast with the MCF-7
experiments where the largest subset of differentially regu-
lated genes was found in the MCF-7 CN 24 h repressed
group (Fig. 4b). The MCF-7 CN repressed signature was
largely composed of a cell cycle arrest profile that was absent
in the MDA-MB-231 expression profile.
The majority of the genes differentially regulated by TGF-β
exposure in the MDA-MB-231 CN cells were similarly regu-
lated in the MDA-MB-231 H2 cells. A substantial portion of
these genes function as components or modulators of the
ECM or as regulators of the adhesive properties of cells (Table
2). Included in this list are several genes encoding collagens,
metalloproteinases (ADAM19, MMP14), and secreted factors
(TGFB1, LTBB2, JAG1, WNT5B) as well as plasminogen reg-
ulating genes (PLAU, SERPINE1/PAI-1). The genes outside
the MDA-MB-231 (CN and H2) overlap mostly consist of TGF-
β gene inductions potentiated by HER-2 overexpression.
Many of these TGF-β potentiated genes could be classified as
'pro-malignancy' genes or as genes associated with aggres-
sive, invasive or highly angiogenic tumors. For example, four
independent elements representing vascular endothelial
growth factor (VEGF) were upregulated in the MDA-MB-231
H2 cells, as was the angiopoietin-like molecule ANGPTL4.
Figure 6
Downregulation of c-myc RNA levels by transforming growth factor (TGF)-β is not observed and is not required for p15INK4B induction in MC -7 cells
(TGF)-β is not observed and is not required for p15INK4B induction in 
MCF-7 cells. RNA and total protein were extracted from the same flasks 
of cells treated for either 6 or 24 h with diluent control or 2 ng/ml TGF-
β1. The protein samples were probed with an anti-p15INK4B antibody as 
in Fig. 4b. The Northern blot re-probed with a glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) sequence and the image of the 28S 
and 18S ribosomal RNAs serve as controls.
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Dominant gene signatures induced by transforming growth factor-β1 in the mesenchymal MDA-MB-231 CN and MDA-MB-231 H2 
cell lines
Sequence namea Sequence descriptionb Fold ∆ MB-231 CNc Fold ∆ MB-231 H2d Gene ontologye
ANGPTL4 Angiopoietin-like 4 3.34 Angiogenesis
EDN1 Endothelin 1 (ET-1) 2.87 2.45 Angiogenesis
VEGF Vascular endothelial growth factor 2.16 (4) Angiogenesis
DAAM1 Dishevelled associated activator of 
morphogenesis 1
3.58 Cytoskeleton regulation
FSCN1 Fascin homolog 1, actin-bundling protein 2.71 Cytoskeleton regulation
KRT7 Keratin 7 1.71 Cytoskeleton regulation
KRTHB1 Keratin, hair, basic, 1 1.70 Cytoskeleton regulation
MYO10 Myosin X 2.13 2.16 Cytoskeleton regulation
NEDD9 Neural precursor cell, developmentally down-
regulated 9
2.56 Cytoskeleton regulation
PLEK2 Pleckstrin 2 4.62 3.80 Cytoskeleton regulation
PODXL Podocalyxin-like 3.07 1.92 Cytoskeleton regulation
PDLIM4 LIM domain protein, Reversion-induced LIM 
protein (RIL)
1.95 Cytoskeleton regulation
SMTN Smoothelin 2.02 Cytoskeleton regulation
SPAG4 Sperm associated antigen 4 2.60 Cytoskeleton regulation
TAGLN Transgelin 2.21 3.35 Cytoskeleton regulation
TPM1 Tropomyosin 1 (alpha) 1.90 (3) 2.42 (3) Cytoskeleton regulation
TUBA3 Tubulin, alpha 3 2.04 Cytoskeleton regulation
COL1A1 Collagen, type I, alpha 1 10.10 18.47 (2) ECM/adhesion
COL4A1 Collagen, type IV, alpha 1 5.08 (2) 3.94 (2) ECM/adhesion
COL4A2 Collagen, type IV, alpha 2 3.10 (2) 2.40 (2) ECM/adhesion
COL5A1 Collagen, type V, alpha 1 3.71 (3) ECM/adhesion
COL6A3 Collagen, type VI, alpha 3 20.61 ECM/adhesion
COL7A1 Collagen, type VII, alpha 1 3.74 (2) ECM/adhesion
FN1 Fibronectin 1 2.22 (4) ECM/adhesion
ITGA2 Integrin, alpha 2 (CD49B, alpha 2, VLA-2 
receptor)
1.85 ECM/adhesion
ITGA5 Integrin, alpha 5 (fibronectin receptor) 2.58 ECM/adhesion
ITGB1 Integrin, beta 1 (fibronectin, receptor, beta) 3.13 ECM/adhesion
LAMC2 Laminin, gamma 2 7.84 (2) ECM/adhesion
MFAP2 Microfibrillar-associated protein 2 2.15 ECM/adhesion
SDC1 Syndecan 1 2.25 (2) ECM/adhesion
THBS1 Thrombospondin 1 5.15 (4) 3.03 (4) ECM/adhesion
CLDN4 Claudin 4 1.78 ECM/adhesion
ADAM19 A disintegrin and metalloproteinase domain 19 2.42 3.12 Protease and inhibitors
FURIN Furin (paired basic amino acid cleaving enzyme) 2.57 2.56 Protease and inhibitors
MMP14 Matrix metalloproteinase 14 (membrane-
inserted)
2.19 1.85 (2) Protease and inhibitors
PRSS3 Protease, serine, 3 (mesotrypsin) 3.19 (2) Protease and inhibitors
PLAU Plasminogen activator, urokinase 2.02 (2) 2.76 (2) Protease and inhibitors/ECM
PLAUR Plasminogen activator, urokinase receptor 1.70 Protease and inhibitors/ECM
SERPINE1 PAI-1 plasminogen activator inhibitor type 1 5.80 (2) 3.74 (3) Protease and inhibitors/ECM
BMP1 Bone morphogenetic protein 1 2.29 Secreted factor
FSTL3 Follistatin-like 3 (secreted glycoprotein) 2.31 3.00 Secreted factor
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JAG1 Jagged 1 (Alagille syndrome) 1.98 1.99 Secreted factor
LTBP2 Latent transforming growth factor-β binding 
protein 2
2.44 3.12 Secreted factor
LTBP3 Latent transforming growth factor-β binding 
protein 3
3.26 Secreted factor
STC1 Stanniocalcin 1 2.99 (2) 2.01 (3) Secreted factor
TGFB1 Transforming growth factor, beta 1 5.77 3.98 (2) Secreted factor
WNT5B Wingless-type MMTV integration site family, 5B 1.80 5.82 Secreted factor
CGB Chorionic gonadotropin, beta polypeptide 18.25 45.95 Secreted factor
ARHB RhoB 2.83 1.91 Signal transduction
ARHD ras homolog gene family, member D 9.26 Signal transduction
CSF1R Colony stimulating factor 1 receptor, (v-fms) 
oncogene
7.16 Signal transduction
EPHB2 EphB2 5.09 6.30 (4) Signal transduction
MADH7 MAD, mothers against decapentaplegic 
homolog 7
2.16 5.79 Signal transduction
MAPK13 Mitogen-activated protein kinase 13 2.28 Signal transduction
MAPK8IP3 Mitogen-activated protein kinase 8 interact. 
protein 3
2.02 Signal transduction
PIK3CD Phosphoinositide-3-kinase, catalytic, delta 
polypeptide
2.46 Signal transduction
RAB31 RAB31, member RAS oncogene family 1.82 Signal transduction
RALB v-ral simian leukemia viral oncogene homolog B 1.93 Signal transduction
SGNE1 Secretory granule, neuroendocrine protein 1 10.38 Signal transduction
SPEC1 Small protein effector 1 of Cdc42 1.92 1.97 Signal transduction
TMEPAI Transmembrane, prostate androgen induced 
RNA
7.85 9.08 Signal transduction
ABL1 v-abl Abelson murine leukemia viral oncogene 1 1.95 Signal transduction
NET1 Neuroepithelial cell transforming gene 1 2.25 (2) Signal transduction
PINK1 phosphatase and tensin homolog (PTEN) 
induced putative kinase 1
1.98 (2) Signal transduction
PORCN Likely ortholog of mouse porcupine homolog, 
PPN
2.49 Signal transduction
PTPRK Protein tyrosine phosphatase, receptor type, K 1.85 2.29 Signal transduction
JUN v-jun sarcoma virus 17 oncogene homolog 
(avian)
1.98 (2) Transcription factor
JUNB jun B proto-oncogene 2.01 8.34 Transcription factor
MONDOA Mlx interactor 2.26 Transcription factor
SOX4 SOX4 gene for SRY (sex determining region Y)-
box 4
1.97 Transcription factor
BHLHB2 Basic helix-loop-helix domain containing, class 
B, 2
4.26 (2) 4.61 (2) Transcription factor
SNAI2 Snail homolog 2 (Drosophila) 2.37 Transcription factor
a,bThe primary sequence names and descriptions for the differentially regulated genes (defined as greater or equal to 1.7-fold changed with a p-
value of < 0.01) were extracted using Rosetta Resolver. Genes from the dominant ontology classes are shown and thus genes with unknown 
function or those not in well represented ontology classes are not listed. The complete set of differentially expressed genes can be found in 
Additional files 6, 7, 8, 9. cFold change in expression of the induced or repressed genes in the MDA-MB-231 CN cell line after a 24 h exposure to 
2 ng/ml recombinant TGF-β1 compared to the diluent treated controls. The number in parentheses after the fold change indicates the number of 
affected elements that were averaged to calculate the fold difference. dFold change in expression of the induced or repressed genes in the MDA-
MB-231 H2 cell line after a 24 h exposure to 2 ng/ml recombinant TGF-β1 compared to the diluent treated controls. The number in parentheses 
to the right of the fold change indicates the number of affected elements that were averaged to calculate the fold difference. eThe gene ontology 
annotation was curated from the Summary Function and GO fields downloaded from SOURCE [105].
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Dominant gene signatures induced by transforming growth factor-β1 in the mesenchymal MDA-MB-231 CN and MDA-MB-231 H2 
cell lines
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rangements, vesicular transport and EMT [65-67], including
PIK3CD, FSCN1 (fascin), DAAM1, SMTN, ARHD (RhoD),
RAB31, a snail homolog (SNAI2) as well as FN1 (fibronectin)
and ITGA5 and ITGB1 (fibronectin receptors) were induced
in the MDA-MB-231 H2 cells.
Discussion
The primary objective of the experiments described in this
report was to evaluate a potential causal role for HER-2 over-
expression in overcoming the growth inhibitory activity of TGF-
β signaling in the early stages of breast cancer. The MCF-7
and ZR-75-1 breast cancer cell lines were chosen for this
analysis because they display features of 'luminal' differentia-
tion, a property shared by the majority of HER-2 amplified pri-
mary breast cancers and cell lines derived from them [68-71].
Luminal cells typically express 'simple' cytokeratins (KRT8/
KRT18) and generally some detectable level of the ER. The
MCF-10A cell line has been previously used as a model to
examine the effect of TGF-β and HER-2 in normal human mam-
mary epithelial cells; however, these cells would be better
classified as breast 'basal/progenitor' cells because they dis-
play KRT5, KRT17, P-cadherin (CDH3) and vimentin (basal
markers) as opposed to luminal markers (data not shown)
Figure 7
Divergent transforming growth factor (TGF)-β gene activation and biological responses in MCF-7 and MDA-MB-231 cell lines. (a,b) The TGF-β 
induced transcriptional program is almost entirely non-overlapping in the luminal MCF-7 and the mesenchymal MDA-MB-231 breast cancer cell 
lines. The number of genes (a) induced and (b) repressed greater than 1.5-fold with a p-value < 0.01 after a 24 h exposure to TGF-β are shown. All 
of the individual genes commonly affected in both control cell lines (MCF-7 CN and MDA-MB-231 CN) are listed below the diagram. (c,d) Model for 
the differential outcomes of TGF-β stimulation in estrogen receptor (ER) positive luminal breast cells compared to ER-negative mesenchymal cells. 
(e,f) Model for context specific effects of HER-2 overexpression on TGF-β signaling in ER-positive luminal cells versus ER-negative mesenchymal 
cells. EMT, epithelial to mesenchymal transition.
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R1073[72]. Although some primary human breast cancers have basal
features, these tumors rarely contain the amplified HER-2
locus [69,73]. We therefore studied the effects of engineered
HER-2 overexpression on TGF-β signaling in the MCF-7 and
ZR-75-1 luminal breast cancer cell lines as it is not yet possi-
ble to routinely culture normal or immortalized (i.e. non-malig-
nant) luminal mammary epithelial cells.
MCF-7 cells are highly sensitive to activated TGF-β at physio-
logically relevant concentrations when cultured on plastic,
making them a useful model for studying TGF-β mediated
growth arrest. The IC90 for TGF-β mediated growth inhibition
for MCF-7 CN cells was about 10 pM, a dose effectively the
same as that defined for this cytokine with the classic mink
lung epithelial cell model, Mv1Lu [74]. We show that the
potent inhibitory effect of TGF-β1 is essentially eliminated in
MCF-7 cells selected for stable overexpression of HER-2. It
should be noted that the level of HER-2 receptors in MCF-7
H2 cells is well within the range observed in clinical samples
when the gene is amplified [10]. The TGF-β induced gene pro-
files generated for the MCF-7 CN and MCF-7 H2 cells are
entirely consistent with the sensitivity differences to growth
inhibition by TGF-β. The majority of the profile detected in the
MCF-7 CN cells was not present in the MCF-7 H2 cells,
including, most notably, a large set of genes that constitute a
clearly recognizable cell cycle arrest signature. This signature
is primarily composed of down-regulated genes involved in
cell-cycle regulation, chromosomal replication, mitosis, cytoki-
nesis, protein synthesis and general metabolism (Table 1). We
have shown by western blot analysis that the cell-cycle arrest
response in MCF-7 CN cells includes the induction of the
p15INK4B dependent kinase inhibitor that is a direct target of
TGF-β induced Smad DNA binding and a central mediator of
TGF-β growth arrest [58,63]. The p15INK4B induction is dura-
ble for at least 1 to 2 cell-cycle periods, suggesting that the 24
h microarray profiles include primary as well as secondary
gene responses.
The induction of well characterized TGF-β target genes,
including p15INK4B, CTGF, and PAI-1, was also found to be
abrogated in a second ER-positive, luminal breast cancer cell
line, ZR-75-1, when HER-2 is overexpressed (Fig. 3). These
cells exhibited a reduction of several key TGF-β pathway mark-
ers that was strikingly similar to the pattern observed in MCF-
7 H2 cells (Fig. 2). The observation that HER-2 overexpression
leads to a similar abrogation of TGF-β signaling in two geneti-
cally diverse breast cancer cell lines strengthens the hypo-
thesis that HER-2 gene amplification contributes to breast
cancer progression in part by blocking the potent growth
inhibitory signals present in normal breast tissue. This function
might be critical to allow a transformed cell previously in con-
tact with the basement membrane to grow unchecked and
avoid apoptosis in the center of a breast duct.
Numerous molecular mechanisms for acquired resistance to
growth inhibition by TGF-β in epithelial cancers have been pro-
posed. Inactivation of the TGF-β receptor complex, either by
deletion or somatic mutation, is important for the genesis of
multiple human malignancies [36], although these mutations
are uncommon in breast cancer. The downstream signal trans-
duction Smad proteins are also targets of mutational inactiva-
tion in some human cancers [37]. Resistance to the anti-
proliferation effects of TGF-β in several cell line models,
including breast cancer, has been attributed to overexpression
of Smad co-repressor proteins [75] such as ski [76,77], sno
[78] and evi-1 [79]. Overexpression and/or mutational activa-
tion of the oncogenes c-myc [80,81] and ras [82-84] have
been reported to directly render cells resistant to TGF-β. Sim-
ilarly, amplification and/or overexpression of the MDM2 gene
have also been associated with TGF-β resistance [47].
It has been previously reported that co-expression of HER-2
and c-Ha-ras can render MCF-10A cells relatively resistant to
the growth inhibitory effects of TGF-β [85]. It was proposed
that the Smad-dependent repression of c-myc is central to the
TGF-β growth arrest program, and that loss of c-myc down-
regulation is the critical defect in MCF-10A cells expressing
HER-2 and c-Ha-ras [85]. Our results show that induction of
p15INK4B expression and the cytostatic effects mediated by
TGF-β do not depend on the repression of c-myc mRNA levels
in MCF-7 cells (Fig. 4). Therefore, a loss of c-myc repression
in MCF-7 H2 cells does not explain the observed TGF-β resist-
ance. MCF-7 cells are not the only example of a cell line
potently inhibited by TGF-β without rapid loss of c-myc expres-
sion [86,87]. Moreover, it is becoming clear that c-myc inde-
pendent mechanisms are important for TGF-β growth
inhibition, even when rapid transient c-myc down-regulation
occurs [88,89].
Our data suggest that defects in HER-2 overexpressing cells
that affect TGF-β responses downstream of Smad nuclear
accumulation and DNA-binding lead to the generalized loss of
growth arrest in luminal breast cancer cells. The elements of
the TGF-β pathway required to activate Smad proteins in
MCF-7 cells are intact as endogenous Smad proteins translo-
cate to the nucleus and bind to specific SBE elements from
the PAI-1 promoter equally well in control and HER-2 cells
upon treatment with TGF-β1. Thus, the effect of HER-2 over-
expression is not analogous to the reported effects of ras on
TGF-β signaling where the nuclear translocation of ectopically
expressed Smad3 was abrogated in the presence of onco-
genic ras [90]. It has been shown that constitutively active raf
leads to alterations in TGF-β signaling without affecting Smad
nuclear localization [91]. Additionally, the oncogenic ras muta-
tions described in the MDA-MB-231 and other cell lines does
not prevent the TGF-β stimulated nuclear localization of Smad
proteins with or without the addition of high level HER-2 (Fig.
6) [92]. The latter studies demonstrated the nuclear transport
of endogenous Smad proteins to the nucleus shortly after
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MB-468 cells) or in the presence of EGF, activated ras, con-
stitutive raf, or pathologically overexpressed HER-2 (data not
shown; Fig. 6).
We used the Affymetrix U133A transcript ratios of the MCF-7
CN compared to the MCF-7 H2 cells to screen for changes in
a large number of molecules previously described to partici-
pate in, or interact with, the TGF-β signaling pathway [93]
(Additional file 10). At least at the level of RNA abundance, we
ruled out many potential candidates including the Smad co-
repressors ski, sno, SNIP, SIP1 and evi-1. Furthermore, we did
not detect expression differences in the inhibitory Smad (I-
Smad) proteins in the MCF-7 H2 cells, which rules out one
mechanism (transcription up-regulation of SMAD7) employed
by cytokines such as interferon gamma, tumor necrosis factor-
alpha and interleukin-1 to inhibit TGF-β signaling [39]. The
most straight forward and promising message differences
observed in the MCF-7 CN versus MCF-7 H2 comparisons
are the modest but reproducible up-regulation of the protein
TGIF [75,94], a homeodomain transcriptional repressor pro-
tein thought to recruit histone deacetylases, and decreased
expression of two CBP/p300 interacting proteins, PCAF and
CITED2. Future work will be needed to validate the possible
mechanistic leads that are suggested by these expression
data. In addition, the critical defect(s) in the HER-2 overex-
pressing cells may be the result of post-transcriptional
changes that alter specific protein-protein or protein-DNA
interactions.
The biological effects and transcriptional program induced by
TGF-β in the mesenchymal MDA-MB-231 breast cancer cells
is very different from that observed in the luminal breast cancer
cells. It is unlikely that the non-overlapping signatures is a
result primarily of false positives or random genetic drift as
many of the genes induced and repressed in both cell lines
(MDA-MB-231 and MCF-7) have been previously described
as TGF-β targets in a variety of systems. For example, we
found 9/17 genes previously published as TGF-β inducible
after 4 h in MDA-MB-231 cells [85] (Table 1) to be similarly
induced in the 6 h TGF-β expression profile of MDA-MB-231
CN cells (Additional file 6). Genes encoding ECM compo-
nents and modifying proteins, as well as genes encoding pro-
teins thought to contribute to motility, invasion and as markers
of EMT, were predominantly induced in the MDA-MB-231
cells but not in the MCF-7 cells. Recent data suggest that the
snail/slug family of zinc-finger transcriptional repressors are
central mediators of EMT, in part by repressing the expression
of the tight-junction protein E-cadherin (CDH1) and by induc-
ing critical regulators of the cytoskeleton such as RhoD [95-
99]. Furthermore, TGF-β can induce snail family proteins in
some contexts [100], a link that may help explain the mecha-
nism by which TGF-β contributes to EMT and cancer progres-
sion. Recently, it has been shown that the expression of snail
is regulated by MTA3, which is in turn regulated by ER signal-
ing [101,102]. The finding that snail expression is blocked by
an active ER signaling pathway has critical implications for
breast cancer and could potentially explain why the EMT pro-
gram is not induced by TGF-β in ER-positive breast cancer
cells.
The observation that the effects of HER-2 overexpression on
TGF-β responses in breast cancer cells is highly context
dependent could be explained, for example, by a model in
which two major branches of TGF-β responses exist: one that
is inhibited by active ER signaling and the other that is inhib-
ited by constitutive, high level ras/MAPK signaling (Fig. 7c,d).
This model could also be a framework to explain the composi-
tion and size of the TGF-β induced transcriptional response
signatures that we observed in each of the four cell lines pro-
filed. Thus, in ER-positive cells without constitutive ras/MAPK
signaling (i.e. MCF-7), TGF-β primarily induces a robust cell
cycle arrest program (Figs 4 and 7c). HER-2 overexpression
without the loss of ER signaling, as is the case in the MCF-7
H2 cells (data not shown), abrogates the TGF-β induced cell
cycle arrest program. As the EMT program is still repressed,
however, the overall gene expression alterations induced by
TGF-β is minimal (Figs 4 and 7e). On the other hand, in an ER-
negative cell with a constitutively active ras/MAPK pathway
(i.e. MDA-MB-231), TGF-β induces the expression of snail and
thereby the expression of an EMT transcriptional program that
is almost non-overlapping with the TGF-β signature observed
in the MCF-7 cells (Figs 4 and 7d). Finally, when HER-2 is
overexpressed in an ER-negative cell (MDA-MB-231 H2), it
appears to synergize with the TGF-β pathway to induce an
even larger pro-invasion, angiogenesis, and EMT signature
(Figs 4 and 7f).
Consistent with our results and this model, HER-2 and the ras/
MAPK pathway have been previously reported to synergize
with TGF-β signals to promote invasive behavior and metasta-
sis [55,56,103,104]. For example, bitransgenic MMTV-neu/
MMTV-TGF-β1 mice exhibited higher levels of circulating
tumor cells and lung metastasis than the MMTV-neu mice and
the tumors from the bigenic mice had higher levels of vimentin
as well as activated Smad2, Akt, and MAPK [103]. Synergistic
effects of HER-2 and TGF-β on the motility of the ER-negative
mammary epithelial cell line MCF-10A have also been
described [104]. In both of these examples, HER-2 overex-
pression resulted in an increase in TGF-β mediated Smad acti-
vation/activity. Thus, one could hypothesize that increased
signaling via the HER-2/ras/MAPK pathway could increase
Smad-dependent gene activation and explain the much larger
TGF-β signature and biological properties observed in the
MDA-MB-231 H2 cells. We have observed evidence of auto-
crine TGF-β signaling and EMT in a few examples of HER-2
amplified (ER-negative) cancer cell lines, such as SKOV3 and
HCC1569 (data not shown). This pro-metastatic activity pro-
moted by HER-2 could explain how the HER-2 amplification
event may contribute to clinically late-stage disease and to the
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7] in addition to its role in breast cancer initiation.
Conclusion
The gene expression profiles and in vitro assays presented in
this report demonstrate that the interaction of overexpressed
HER-2 and the TGF-β pathway is complex and highly depend-
ent on the cellular background. In luminal breast cancer cells,
HER-2 overexpression can block TGF-β mediated cell cycle
arrest by a previously unreported mechanism that does not
involve the abrogation of Smad nuclear accumulation, DNA
binding or changes in c-myc repression. Conversely, in the
post-EMT context, HER-2 and TGF-β can cooperate to
increase the malignant potential of breast cancer cells. These
latter, seemingly synergistic effects of elevated HER-2 and
TGF-β signaling could provide a rationale for using combined
biological therapies that target these two pathways.
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